High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

2020 ◽  
Author(s):  
Wei Cao ◽  
Xiaosheng Liu ◽  
Ke Hong ◽  
Zhiyong Ma ◽  
Yuelun Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Intravenous Immunoglobulin ◽  
High Dose

scholarly journals Corrigendum: High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei Cao ◽  
Xiaosheng Liu ◽  
Ke Hong ◽  
Zhiyong Ma ◽  
Yuelun Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Intravenous Immunoglobulin ◽  
High Dose

scholarly journals High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China

2021 ◽  
Vol 12 ◽  
Author(s):  
Wei Cao ◽  
Xiaosheng Liu ◽  
Ke Hong ◽  
Zhiyong Ma ◽  
Yuelun Zhang ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Intravenous Immunoglobulin ◽  
Standard Therapy ◽  
Proportional Hazards ◽  
Disease Onset ◽  
Case Series ◽  
Cox Proportional Hazards ◽  
High Dose ◽  
Kaplan Meier ◽  
High Dose Ivig

BackgroundThe effective treatment of coronavirus disease 2019 (COVID-19) remains unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in cases of severe COVID-19, but evidence from larger case series is still lacking.MethodsA multi-center retrospective study was conducted to evaluate the effectiveness of IVIg administered within two weeks of disease onset at a total dose of 2 g/kg body weight, in addition to standard care. The primary endpoint was 28-day mortality. Efficacy of high-dose IVIg was assessed by using the Cox proportional hazards regression model and the Kaplan-Meier curve adjusted by inverse probability of treatment weighting (IPTW) analysis, and IPTW after multiple imputation (MI) analysis.ResultsOverall, 26 patients who received high-dose IVIg with standard therapy and 89 patients who received standard therapy only were enrolled in this study. The IVIg group was associated with a lower 28-day mortality rate and less time to normalization of inflammatory markers including IL-6, IL-10, and ferritin compared with the control. The adjusted HR of 28-day mortality in high-dose IVIg group was 0.24 (95% CI 0.06–0.99, p<0.001) in IPTW model, and 0.27 (95% CI 0.10–0.57, p=0.031) in IPTW-MI model. In subgroup analysis, patients with no comorbidities or treated in the first week of disease were associated with more benefit from high-dose IVIg.ConclusionsHigh-dose IVIg administered in severe COVID-19 patients within 14 days of onset was linked to reduced 28-day mortality, more prominent with those having no comorbidities or treated at earlier stage.

scholarly journals Neutropenia resulting from high‐dose intravenous immunoglobulin in dermatological patients

2020 ◽  
Vol 18 (12) ◽  
pp. 1394-1403
Author(s):  
Johanna Stoevesandt ◽  
Johanna Heitmann ◽  
Matthias Goebeler ◽  
Sandrine Benoit
Keyword(s):  
Intravenous Immunoglobulin ◽  
High Dose
Sign in / Sign up

Export Citation Format

Share Document